AUROPHARMA

SUNPHARMA

WHICH STOCK IS GOOD

SUNPHARMA OR AUROPHAMRA Aurobindo Pharma – More Investable at the Moment Reasons: ✅ Valuation Comfort: Trades at a much lower P/E (≈19–21x) vs. Sun Pharma’s high P/E (~40x) — suggesting limited downside risk. ✅ Room to expand PE multiple as earnings improve. ✅ Lower base = higher upside potential. Sun Pharma – Still Strong but Not at Best Entry Point Why Caution: • High Valuation: P/E over 40x could limit immediate upside. • Price near resistance zones (as per typical weekly charts). • Good for long-term holding, but not a fresh entry technically. Key Insights from the Chart: 🔵 Sun Pharma • Has delivered ~11,972% returns, clearly outperforming. • But it already had its massive bull run, and current valuations (PE ~40) reflect much of that optimism. • Appears to be in a distribution/sideways phase after exponential growth. 🔴 Aurobindo Pharma • Returned ~4,697%, still a strong performance — but half of Sun Pharma. • Visibly underperformed post-2020, creating valuation comfort and room for a catch-up. • Currently showing signs of base formation and re-rating potential — ideal for contrarian investing. 🔷 Nifty Pharma Index • Gained ~2,113%, showing Aurobindo has outperformed the sector, but still has potential to re-test previous highs.